COLA: Atopic Dermatitis

Session recorded on August 25, 2017.

Speaker: Luz Fonacier, MD

Viewers can earn credit by completing the posttest questions.

Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease that affects children and adults. Patients with moderate-to-severe AD often receive little benefit from current treatment therapies. The only FDA-approved systemic treatment option for these patients is systemic steroids. Second line therapy for AD (not yet approved by the FDA) includes a host of immunosuppressants, which are not indicated for AD and may have serious adverse effects. New research on the immune pathogenesis of AD has paved the way for new, targeted, systemic therapies for AD; clinicians need help integrating these new therapies into current treatment paradigms. This video covers the pathogenesis of AD, the associated features, how to determine disease severity, the biomarkers, the triggers, and the therapeutic options of AD.

Target Audience

Practicing Allergists / Immunologists

Learning Objectives

After viewing the video recording, learners should be able to…

  • Identify common "mimics" of AD
  • Discuss the workup of AD
  • Discuss treatments of AD
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

Luz Fonacier, MD, Speaker
Principal Investigator, Contracted Research: Baxter, Genentech
Substitute Investigator, Contracted Research: Merck
Advisory Board/Consultant/Speaker, Fees/Honorarium: Regeneron

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Luz Fonacier, MD
Professor of Clinical Medicine
SUNY at Stony Brook
Section Head of Allergy
Training Program Director

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
Course expires: 


Please login or create an account to take this course.